bioRxiv · 10.64898/2026.11.12.765663
Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies
Abstract
Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Le, C. C., Weng, J., Liu, J., Aletti, F. M., Cherng, X., Tang, Y., Patchva, S., Richard, M., Balakumaran, M., Piubelli, M. M., Solis Soto, L. M., Lu, W., Lin, C.-Y., Chu, F., Cao, J., Rehman, A., Singh, K., Agbedia, O., Gouni, S., Chohan, K., Darbaniyan, F., Kolsuz, S., Balakrishnan, K., Saini, N., Green, M. R., Flowers, C. R., Iyer, S., Vega, F., Neelapu, S. S.. 2026-11-16. Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies. https://doi.org/10.64898/2026.11.12.765663
Cite the original work for its findings. Save a collection to share your selection of sources.